Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader

被引:17
|
作者
Zhu, Cheng-Liang [2 ,4 ,7 ]
Luo, Xiaomin [1 ]
Tian, Tian [3 ]
Rao, Zijian [2 ]
Wang, Hanlin [10 ]
Zhou, Zhesheng [2 ]
Mi, Tian [5 ]
Chen, Danni [2 ]
Xu, Yongjin [9 ]
Wu, Yizhe
Che, Jinxin [3 ]
Zhou, Yubo [1 ,5 ,6 ]
Li, Jia [1 ,5 ,6 ]
Dong, Xiaowu [3 ,7 ,8 ]
机构
[1] Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
[2] Zhejiang Univ, Inst Pharmacol & Toxicol, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310058, Peoples R China
[3] Zhejiang Univ, Hangzhou Inst Innovat Med, Inst Drug Discovery & Design, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China
[4] Ctr Drug Safety Evaluat & Res ZJU, Hangzhou 310058, Peoples R China
[5] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[6] Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan Tsuihang New Di 528400, Guangdon, Peoples R China
[7] Zhejiang Univ, Innovat Inst Artificial Intelligence Med, Hangzhou 310016, Peoples R China
[8] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Peoples R China
[9] Canc Hosp Univ Chinese Acad Sci, Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc, Hangzhou 310005, Peoples R China
[10] Fudan Univ, Sch Pharm, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
AKT; Protein kinase B; PROTAC; Chemical degrader; Rational design; MANTLE CELL LYMPHOMA; BIOLOGICAL EVALUATION; PATHWAY; DEGRADATION; INHIBITION; DERIVATIVES; BTK; IBRUTINIB; MK-2206; TARGET;
D O I
10.1016/j.ejmech.2022.114459
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
AKT and associated signaling pathways have been recognized as promising therapeutic targets for decades, and growing evidence indicates that inhibition or degradation of cellular AKT are viable strategies to treat cancer. Guided by an in silico modeling approach for rational linker design and based on our previous work in this field, we herein efficiently synthesized a small group of cereblon-recruiting AKT PROTAC molecules and identified a highly potent AKT degrader B4. Compared to the existing AKT degraders, B4 has a structurally unique AKT targeting warhead derived from the pyrazole-furan conjugated piperidine derivatives. It induces selective degradation of all three isoforms of AKT and exhibits efficacious anti-proliferation against several human hematological cancers. Notably, B4 demonstrates potent inhibition of AKT downstream signaling superior to its parental inhibitor. Together with its active analogs, B4 expands the arsenal of AKT chemical degraders as a valuable probe to uncover AKTs new functions and as a potential drug candidate to treat cancer.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Structure-based design of Trifarotene, a potent and selective RAR agonist for the treatment of acne
    Thoreau, E.
    Arlabosse, J.
    Bouix-peter, C.
    Chambon, S.
    Chantalat, L.
    Daver, S.
    Dumais, L.
    Duvert, G.
    Feret, A.
    Ouvry, G.
    Pascau, J.
    Raffin, C.
    Rodeville, N.
    Soulet, C.
    Tabet, S.
    Talano, S.
    Portal, T.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (09) : B17 - B17
  • [42] Structure-based design of a potent and selective peptide inhibitor of caspase-3
    Yoshimori, A
    Takasawa, R
    Sakai, J
    Kobayashi, T
    Sunaga, S
    Tanuma, SI
    FEBS JOURNAL, 2005, 272 : 523 - 523
  • [43] Structure-based design of potent and selective tankyrase inhibitors to target the Wnt pathway
    Hua, Zihao
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [44] Structure-based design of potent and selective CGRP receptor antagonists for the treatment of migraine
    Bell, Ian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [45] Structure-Based Design of Potent and Selective Leishmania N-Myristoyltransferase Inhibitors
    Hutton, Jennie A.
    Goncalves, Victor
    Brannigan, James A.
    Paape, Daniel
    Wright, Megan H.
    Waugh, Thomas M.
    Roberts, Shirley M.
    Bell, Andrew S.
    Wilkinson, Anthony J.
    Smith, Deborah F.
    Leatherbarrow, Robin J.
    Tate, Edward W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (20) : 8664 - 8670
  • [46] Discovery of novel TLR8 antagonists via structure-based rational design
    Jiang, Shuangshuang
    Zhang, Shuting
    Hu, Zhenyi
    Tanji, Hiromi
    Shimizu, Toshiyuki
    Yin, Hang
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [47] Rational, structure-based design of mRNA therapeutics
    Hall, Michelle
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [48] Structure-based design of potent histatin analogues
    Brewer, D
    Lajoie, G
    BIOCHEMISTRY, 2002, 41 (17) : 5526 - 5536
  • [49] Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia
    Liu, Wenyan
    Bai, Yu
    Zhou, Licheng
    Jin, Jian
    Zhang, Meiying
    Wang, Yongxing
    Lin, Runfeng
    Huang, Weixue
    Ren, Xiaomei
    Ma, Nan
    Zhou, Fengtao
    Wang, Zhen
    Ding, Ke
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 264
  • [50] Apamin as a Template for Structure-Based Rational Design of Potent Peptide Activators of p53
    Li, Chong
    Pazgier, Marzena
    Liu, Min
    Lu, Wei-Yue
    Lu, Wuyuan
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2009, 48 (46) : 8712 - 8715